Minerva gastroenterology最新文献_第3页

Barrier and protective effects of a newly developed medical device for the treatment of gastroesophageal reflux disease. 一种新开发的治疗胃食管反流病的医疗装置的屏障和保护作用。

IF 1.9

Minerva gastroenterology Pub Date : 2025-02-27 DOI: 10.23736/S2724-5985.25.03755-6

Federico Benetti, Elisa Gaio, Stefano Agostini

{"title":"Barrier and protective effects of a newly developed medical device for the treatment of gastroesophageal reflux disease.","authors":"Federico Benetti, Elisa Gaio, Stefano Agostini","doi":"10.23736/S2724-5985.25.03755-6","DOIUrl":"https://doi.org/10.23736/S2724-5985.25.03755-6","url":null,"abstract":"Background: Gastroesophageal reflux disease is a clinical condition due to the reflux of stomach contents and leading either to erosive or non-erosive disease. Repeated exposure of esophagus to hydrochloric acid, pepsin, bile salts and pancreatic enzymes in gastric contents damages esophageal mucosa, causing inflammation and increased paracellular permeability. A possible therapy for gastroesophageal reflux disease should hinder gastroesophageal reflux and provide esophageal mucosal protection against all aggressive components. The medical device (Med) tested in this study was developed for the treatment of gastroesophageal reflux disease with the aim to achieve a barrier to protect esophageal mucosa against reflux damages and neutralization of the acidic pocket in the stomach.Methods: The efficacy of Med in forming a protective barrier was performed in vitro using a cellular model of reconstructed human oral epithelium, monitoring its ability to reduce the passage of substances once the formulation was applied, as well as the subsequent reduction in inflammation and toxic effects after exposure to the Triton X-100 stimulus.Results: The medical device is able of creating an effective barrier at the level of epithelial cells. Its protective action is demonstrated by the ability in reducing toxicity and inflammation induced by an irritant agent.Conclusions: This work shows the promising effects of Med as a therapeutic solution for managing signs and symptoms associated with gastroesophageal reflux, capable of exerting its function through a physical action without compromising the physiological balance of epithelial cells.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylaxis of HBV reinfection and disease in liver transplanted patients: 2024 update on the role of HBIG and cost-effectiveness evaluation. 预防肝移植患者的HBV再感染和疾病：2024年HBIG的作用和成本-效果评估的最新进展

IF 1.9

Minerva gastroenterology Pub Date : 2025-01-30 DOI: 10.23736/S2724-5985.24.03864-6

Stefano Fagiuoli, Alfredo Marzano, Luciano DE Carlis, Paolo DE Simone, Maria Rendina

{"title":"Prophylaxis of HBV reinfection and disease in liver transplanted patients: 2024 update on the role of HBIG and cost-effectiveness evaluation.","authors":"Stefano Fagiuoli, Alfredo Marzano, Luciano DE Carlis, Paolo DE Simone, Maria Rendina","doi":"10.23736/S2724-5985.24.03864-6","DOIUrl":"https://doi.org/10.23736/S2724-5985.24.03864-6","url":null,"abstract":"Hepatitis B virus (HBV) infection is a major global health concern, with liver transplantation (LT) serving as a critical treatment for end-stage liver disease caused by HBV. However, the risk of HBV reinfection after LT remains significant, necessitating effective prophylaxis. Today, the combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide analogues (NUCs) is the standard of care for preventing HBV recurrence post-LT but concerns about the cost of HBIG and access to high-barrier NUCs have led to a reduction in the use, dose, and duration of HBIG in recent years. This review provides an updated analysis of the role of HBIG in preventing HBV recurrence post-LT, alongside a detailed evaluation of its cost-effectiveness, leveraging recent pharmacoeconomic data from Italy. The cost analysis showed that HBIG contributes approximately 12.4% (€ 49,000) to the total lifetime cost of LT-related healthcare (€395,986). Short-term HBIG prophylaxis reduced costs by 11.1%, while lifetime usage increased total costs by only 6.6%. However, the primary cost drivers were renal failure and immunosuppressive therapy. In conclusion, despite advancements in NUCs therapy, HBIG remains a cornerstone of HBV prophylaxis post-LT, particularly in high-risk patients, and discontinuation of HBIG in favor of alternative prophylaxis strategies lacks robust supporting evidence. Tailoring prophylaxis to individual patient needs and risk factors allows for personalized treatment while maintaining efficacy.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Traditional Chinese medicine nursing strategies for regulating gut microbiome in incontinence-associated dermatitis: a prospective study. 中医药护理对尿失禁相关性皮炎患者肠道菌群调节的前瞻性研究。

IF 1.9

Minerva gastroenterology Pub Date : 2025-01-16 DOI: 10.23736/S2724-5985.24.03726-4

Hong Gao, Jiayan Song

引用次数: 0

How to navigate the many direct-to-consumer microbiota analyses and why to use them. 如何浏览众多直接面向消费者的微生物群分析，以及为什么要使用它们。

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-17 DOI: 10.23736/S2724-5985.24.03799-9

Francesco DI Pierro, Alexander Bertuccioli, Massimiliano Cazzaniga, Mariarosaria Matera, Ilaria Cavecchia, Viviana Gerardi, Stefania Piccirelli, Daniele Salvi, Cecilia L Pugliano, Paola Cesaro, Cristiano Spada, Nicola Zerbinati

引用次数: 0

The influence of acupoint scraping combined with traditional Chinese medicine fumigation on gastrointestinal dysfunction and defecation after minimally invasive abdominal surgery. 穴位刮痧联合中药熏蒸对腹部微创手术后胃肠功能紊乱及排便的影响

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-01 Epub Date: 2024-01-29 DOI: 10.23736/S2724-5985.23.03621-5

Min Su, Wanchen Yu, Ying Su

引用次数: 0

Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome. 改善慢性肠易激综合征患者生活质量的特定益生菌和益生元。

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-01 Epub Date: 2024-01-19 DOI: 10.23736/S2724-5985.23.03563-5

Lorenzo Bertani, Linda Balestrini, Lucia Chico, Giulia Della Scala, Francesca Geri, Alessandro Tornar, Claudio Belcari

{"title":"Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome.","authors":"Lorenzo Bertani, Linda Balestrini, Lucia Chico, Giulia Della Scala, Francesca Geri, Alessandro Tornar, Claudio Belcari","doi":"10.23736/S2724-5985.23.03563-5","DOIUrl":"10.23736/S2724-5985.23.03563-5","url":null,"abstract":"Background: Irritable bowel syndrome (IBS) is a chronic disorder with an important impact on patients' quality of life. Although several data indicate that psychological symptoms are frequently reported by patients with IBS, few therapies have been evaluated regarding these issues.Methods: A retrospective observational study was conducted to evaluate the effectiveness of a probiotic-based dietary supplement (Colicron®) in a group of patients with diarrhea-predominant IBS (IBS-D). We included patients treated with Colicron® (1 cps/day for 8 weeks). Primary endpoint was the gastrointestinal symptoms' remission evaluated by Visual Analogue Scale (VAS); secondary endpoint was the impact of the treatment on physical and mental health evaluated by Hospital Anxiety and Depression Score (HADS) and Short Form Health Survey 36 (SF-36). VAS was assessed at week 4 (T4), week 8 (T8) and week 12 (T12), whereas HADS and SF-36 were performed even at the start of the Colicron® treatment (T0).Results: An improvement of VAS Score was observed at T8 (P<0.001) and T12 (P<0.05) compared to T4. Lower HADS-A (anxiety subdomain) score was obtained at each time point versus T0 (P<0.01), and higher scores of all SF-36 domains were observed during the treatment (0.05<P<0.001) compared to baseline. Moreover, HADS-D (depression subdomain) score, correlated positively, at T0 (P<0.05) and T4 (P<0.05) with the age, as well as a positive correlation was detected between disease duration (P<0.05) and age of patients (P<0.001).Conclusions: Colicron® could be useful in improving both gastrointestinal and psychological symptoms in IBS-D patients. Further prospective clinical trials are needed to confirm these preliminary data.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"413-421"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The diagnostic capability of i-scan for early gastric cancer detection: a systematic review and meta-analysis. i-scan 检测早期胃癌的诊断能力：系统综述和荟萃分析。

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-01 Epub Date: 2024-06-26 DOI: 10.23736/S2724-5985.24.03702-1

Andrew Canakis, Kourosh Kalachi, Jay Bapaye, Nevin Varghese, Benjamin Twery, Jerrold S Canakis

{"title":"The diagnostic capability of i-scan for early gastric cancer detection: a systematic review and meta-analysis.","authors":"Andrew Canakis, Kourosh Kalachi, Jay Bapaye, Nevin Varghese, Benjamin Twery, Jerrold S Canakis","doi":"10.23736/S2724-5985.24.03702-1","DOIUrl":"10.23736/S2724-5985.24.03702-1","url":null,"abstract":"Background: I-scan is an image enhancing technology that utilizes contrast, surface, and tone enhancement to examine the microvascular and microsurface structures of mucosa. Its ability to diagnosis GC is of growing interest due to its ability to make an optical diagnosis; however, only a handful of studies have explored its role in this setting. We aimed to investigate the diagnostic capability of i-scan for GC detection.Methods: Multiple databases were searched for studies utilizing i-scan for GC detection until February 2024. Primary outcomes included the pooled sensitivity, specificity, and accuracy.Results: Seven studies were included (371 patients, 220 GC lesions). The pooled sensitivity was 84% (four studies, 95% CI: 0.65; 0.93), specificity was 83% (three studies, 95% CI: 0.68; 0.92) and accuracy was 84% studies (N.=3, 95% CI: 0.69; 0.93).Conclusions: I-scan appears to be an effective diagnostic tool for GC. However, the functional capabilities related to brightness detection may limits use. Further prospective, comparative studies are needed to determine its role in clinical practice compared to white light endoscopy, narrow band imaging and chromoendoscopy.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"399-404"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upadacitinib in Crohn's disease: real-world experience. 乌达帕替尼治疗克罗恩病：真实世界的经验。

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-01 Epub Date: 2023-12-21 DOI: 10.23736/S2724-5985.23.03594-5

Adil S Mir

引用次数: 0

Clinical experience and treatment of bilateral breast metastasis induced by signet ring cell carcinoma of stomach. 胃标志环细胞癌诱发双侧乳房转移的临床经验和治疗方法。

IF 1.9

Minerva gastroenterology Pub Date : 2024-12-01 Epub Date: 2024-03-21 DOI: 10.23736/S2724-5985.24.03660-X

Jiaxing Luo, Haiguang Liu, Ouchen Wang

引用次数: 0

Clinical application of laparoscopic spleen-preserving distal pancreatectomy in patients with situs inversus totalis. 腹腔镜保脾远端胰腺切除术在全胰腺坐位不全患者中的临床应用。